Abbvie (ABBV)

Trade ABBV now with
12/14/2018 2:15:54 AM BioArctic Outlicenses Its Alpha-synuclein Antibody Portfolio For Parkinson's Disease To AbbVie After Receiving Clearance
12/13/2018 1:06:21 PM AbbVie (ABBV) Announces $5 Bln Stock Repurchase Plan
11/30/2018 10:08:00 AM Pfizer To Pay Royalties To AbbVie For Licensing Its HUMIRA Patents; AbbVie To Make No Payments To Pfizer
11/15/2018 3:02:20 AM Mission Therapeutics, AbbVie Sign DUBs Collaboration In Alzheimer’s And Parkinson’s Disease
11/6/2018 4:45:56 PM AbbVie Announces Patent License Agreements With Momenta Over Proposed Biosimilar Adalimumab Product
11/2/2018 7:48:59 AM AbbVie Q3 GAAP EPS $1.81; Adjusted EPS $2.14
11/1/2018 11:14:19 PM BioArctic's Partner AbbVie Exercises Option To License Alpha-synuclein Antibody Portfolio For Parkinson's Disease
11/1/2018 12:08:01 AM AbbVie Receives European Commission Approval Of VENCLYXTO Plus Rituximab For Chronic Lymphocytic Leukemia
10/24/2018 4:57:01 PM Galapagos, AbbVie Announce Restructuring Of Cystic Fibrosis Alliance
10/24/2018 4:53:09 PM AbbVie To Assume Full Development, Commercial Control Of Cystic Fibrosis Research Program
10/23/2018 9:18:32 AM AbbVie Announces New Patient-reported Outcomes Data From Phase 3 SELECT-MONOTHERAPY Trial On Upadacitinib
10/22/2018 6:03:54 PM AbbVie Announces Positive Results From U-ACHIEVE, An Ongoing Phase 2b/3 Dose-ranging Study On Upadacitinib
10/18/2018 8:52:35 AM AbbVie To Grant To Fresenius Kabi Non-exclusive License To AbbVie's Intellectual Property Relating To HUMIRA